Andrew A. Spencer
Distinguished in Febrile Neutropenia

Dr. Andrew A. Spencer

General Surgery
1959 Ne Pacific St Box #356410, 
Seattle, WA 
Distinguished in Febrile Neutropenia
1959 Ne Pacific St Box #356410, 
Seattle, WA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Andrew Spencer is a General Surgeon in Seattle, Washington. Dr. Spencer is rated as a Distinguished provider by MediFind in the treatment of Febrile Neutropenia. His top areas of expertise are Febrile Neutropenia, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Small Lymphocytic Lymphoma (SLL), and Bone Marrow Transplant.

His clinical research consists of co-authoring 273 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Febrile Neutropenia.

Specialties
General Surgery
Licenses
Surgery in WA
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

1959 Ne Pacific St Box #356410, Seattle, WA 98195

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)
A Phase II, Open Label, Randomized, Two-Arm Study to Investigate the Efficacy and Safety of Two Doses of the Antibody Drug Conjugate GSK2857916 in Participants With Multiple Myeloma Who Had 3 or More Prior Lines of Treatment, Are Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent and Have Failed an Anti-CD38 Antibody (DREAMM 2)
Enrollment Status: Completed
Publish Date: September 03, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin Frozen Liquid, Belantamab Mafodotin Lyophilized Powder
Study Phase: Phase 2
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
A Phase III, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Single Agent Belantamab Mafodotin Compared to Pomalidomide Plus Lowdose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) (DREAMM 3)
Enrollment Status: Active_not_recruiting
Publish Date: June 10, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Pom/Dex (Pomalidomide plus Low Dose Dexamethasone)
Study Phase: Phase 3
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma - DREAMM-6
A Phase I/II, Open-label, Dose Escalation and Expansion Study to Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-Drug Conjugate GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma - DREAMM-6
Enrollment Status: Completed
Publish Date: March 18, 2025
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Lenalidomide, Dexamethasone, Bortezomib
Study Phase: Phase 1/Phase 2
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma
DREAMM 7: A Multicenter, Open-Label, Randomized Phase III Study to Evaluate the Efficacy and Safety of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (B-Vd) Compared With the Combination of Daratumumab, Bortezomib and Dexamethasone (D-Vd) in Participants With Relapsed/Refractory Multiple Myeloma
Enrollment Status: Active_not_recruiting
Publish Date: October 24, 2024
Intervention Type: Drug
Study Drugs: Belantamab Mafodotin, Daratumumab, Bortezomib, Dexamethasone
Study Phase: Phase 3
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
A Phase 3 Randomized, Controlled, Open-label Study of Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)
Enrollment Status: Completed
Publish Date: August 21, 2024
Intervention Type: Drug
Study Drugs: Selinexor, Bortezomib, Dexamethasone
Study Phase: Phase 3
View 4 Less Clinical Trials

269 Total Publications

Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.
Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 08, 2025
Similar Doctors
Experienced in Febrile Neutropenia
Dr. Yarrow J. Mcconnell
General Surgery | Surgical Oncology
Experienced in Febrile Neutropenia
Dr. Yarrow J. Mcconnell
General Surgery | Surgical Oncology

Multicare Health System

4700 Point Fosdick Dr, 
Gig Harbor, WA 
 (27.2 miles away)
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Yarrow Mcconnell is a General Surgeon and a Surgical Oncologist in Gig Harbor, Washington. Dr. Mcconnell is rated as an Advanced provider by MediFind in the treatment of Febrile Neutropenia. Her top areas of expertise are Paget Disease of the Breast, Breast Cancer, Intraductal Papilloma, Angiosarcoma, and Lymphadenectomy. Dr. Mcconnell is currently accepting new patients.

Experienced in Febrile Neutropenia
Dr. Melissa Wong
General Surgery | Transplant Surgery
Experienced in Febrile Neutropenia
Dr. Melissa Wong
General Surgery | Transplant Surgery

Public Hospital Dist No 1 Skagit

1400 E Kincaid St, 
Mount Vernon, WA 
 (53.0 miles away)
360-428-2500
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Melissa Wong is a General Surgeon and a Transplant Surgeon in Mount Vernon, Washington. Dr. Wong is rated as an Advanced provider by MediFind in the treatment of Febrile Neutropenia. Her top areas of expertise are Liver Failure, Alcoholic Cirrhosis, Hepatitis, Kidney Transplant, and Simultaneous Pancreas Kidney Transplant. Dr. Wong is currently accepting new patients.

Experienced in Febrile Neutropenia
Dr. Rebecca A. Stark
Pediatric Surgery | General Surgery
Experienced in Febrile Neutropenia
Dr. Rebecca A. Stark
Pediatric Surgery | General Surgery

The Association Of Chrmc And University Physicians

4800 Sand Point Way Ne, 
Seattle, WA 
 (1.6 miles away)
206-526-2000
Languages Spoken:
English, Castilian, German, Korean, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Rebecca Stark is a Pediatric Surgeon and a General Surgeon in Seattle, Washington. Dr. Stark is rated as an Advanced provider by MediFind in the treatment of Febrile Neutropenia. Her top areas of expertise are Hernia, Congenital Diaphragmatic Hernia, Diaphragmatic Hernia, Appendicitis, and Appendectomy. Dr. Stark is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Spencer's expertise for a condition
ConditionClose
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile